WO2001005403A1 - Medicaments pour soigner les parodontopathies - Google Patents
Medicaments pour soigner les parodontopathies Download PDFInfo
- Publication number
- WO2001005403A1 WO2001005403A1 PCT/JP2000/004832 JP0004832W WO0105403A1 WO 2001005403 A1 WO2001005403 A1 WO 2001005403A1 JP 0004832 W JP0004832 W JP 0004832W WO 0105403 A1 WO0105403 A1 WO 0105403A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- group
- linear
- alkyl group
- branched
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the present invention relates to an agent for periodontal disease comprising a methanebisphosphonic acid derivative or a hydrate thereof as an active ingredient.
- Periodontal disease is a disease of tissues, such as gums, cement trade, periodontal ligament, alveolar bone, and supporting bone, as periodontal tissue surrounding and supporting the teeth. That is, periodontal disease includes gingivitis or so-called periodontal disease including periodontitis, as well as diseases in the pulp tissue such as the initial process of apical periodontitis resulting from inflammation or necrosis of the pulp. Periodontal disease includes inflammation, destruction and degeneration of the periodontal tissue surrounding mammalian teeth and supporting structures. Periodontal tissue includes gingival sulcus epithelium, junctional epithelium, peripheral epithelium, gingiva, alveolar bone, periodontal ligament and cementum.
- Periodontal disease is caused by gingivitis and periodontitis depending on the degree of disease progression. being classified.
- Gingivitis refers to inflammation limited to the gingiva, no lesions in the bone or periodontal ligament, and pockets in a pseudo-blurred or soft state. In principle, the bottom of the pocket is located below the cement enamel boundary, and there is no attachment loss.
- Periodontitis refers to a condition in which gingival inflammation extends to the periodontal ligament and alveolar bone, the pocket becomes a periodontal pocket, and the attachment level (position of attachment) is apical from the cement enamel boundary. As the periodontal pockets deepen, the inflammation persists and progresses deeper.
- Tissue destruction due to periodontal disease is mainly due to plaque adhering between teeth and gums.
- tissue-soluble enzymes and toxins produced by bacteria contained in plaque directly cause tissue destruction, or plaque bacterial products cause inflammation and immune response in periodontal tissue, Cells (such as leukocytes) indirectly cause tissue destruction.
- the tissues targeted for tissue destruction are mainly the sarcoma epithelium, the conjunctival epithelium, and the gingiva, and exhibit the above-mentioned gingivitis, but as the invasion of harmful substances from plaque continues, Inflammation spreads deeply, destroying gingival tissue, reducing and regressing, causing apical movement of the junctional epithelium, detaching the junctional epithelium from the tooth surface, causing attachment loss, and forming periodontal pockets Is done. As the pocket size increases, subgingival plaque increases and the lesion progresses further.
- B lymphocytes stimulated by macrophages produce antibodies, resulting in the formation of an antigen-antibody complex (immune complex).
- This complex activates complement, increases vascular permeability, and induces neutrophil chemotaxis.
- Neutrophils phagocytose these immune complexes but at the same time release lysosomal enzymes into surrounding tissues, further promoting tissue destruction.
- LPS and other toxins released from plaque bacteria, brostaglandin E 2 (PGE 2 ) ', and macrophages, which are inflammatory cells (immunocompetent cells), are activated to activate osteoclasts.
- T lymphocytes It is thought that osteoclast activator released by E. coli and inter-lipin-1 and inter-leukin-16 released by macrophage are involved. As the alveolar bone destruction progresses, the bearing capacity of the teeth will eventually decrease, resulting in tooth loss.
- Antibiotics are used to treat plaque bacteria in the treatment of periodontal disease, but this treatment is not a long-term treatment.
- Home care such as gargling, brushing, and the use of dental floss, can help control periodontal disease. Improving local blood supply by using gingival pine surge at the time of pushing is also effective in controlling the progress of periodontal disease.
- Other preventative treatments there is hydrogen peroxide gargle (3% H 2 ⁇ 2 in warm water).
- Peroxides Karupamido urea hydrogen peroxide, CH S N 2 ⁇ 3 is also used in the local treatment of inflammation in slight infection and periodontitis.
- Another method of treating periodontal disease is to use non-steroidal anti-inflammatory drugs to control the progress of the disease.
- U.S. Pat. No. 4,667,132 states that Etodo 1ac, an analgesic and anti-inflammatory agent, can suppress bone loss associated with bone resorption and periodontal disease .
- U.S. Pat. No. 4,440,779 discloses the use of a novel anti-inflammatory agent for the treatment of pain and inflammatory conditions associated with arthritis, spondylitis, gout, periodontal disease, etc. Is described.
- N-aralkylamino-1-hydroxyalkane-1,1-bisphosphonic acid derivatives as effective for the treatment of degenerative diseases, inflammation, osteoporosis, periodontitis and hyperthyroidism Is disclosed.
- Japanese Patent Application Laid-Open No. 1-197495 discloses the use of an aromatic-substituted azacycloalkylalkanebisphosphonic acid for disorders in which calcium metabolism disorder or abnormal deposition of poorly soluble calcium salt is observed. It refers to periodontitis or periodontitis.
- methanebisphosphonic acid has an anti-inflammatory effect, an anti-rheumatic effect, a bone metabolic disease improving effect, an interleukin-1 production / action suppressing effect, and an antioxidant effect.
- Derivatives are disclosed, but no mention is made of effects on periodontal diseases such as periodontal disease and apical periodontitis.
- An object of the present invention is to provide a novel agent for periodontal disease that solves the above-mentioned problems of the prior art. Disclosure of the invention
- the present inventors have proposed that a methanebisphosphonic acid derivative represented by the following general formula (I) or a hydrate thereof suppresses infiltration of inflammatory cells such as leukocytes in the respiratory region due to periodontal disease. For example, they found that they were useful as agents for periodontal disease, and thus completed the present invention.
- X is a straight or branched chain having 1 to 8 carbon atoms, and is unsubstituted or an alkyl group having a substituent of nitrogen, oxygen or silicon atom, phenyl group or naphthyl group (phenyl, A naphthyl group may be substituted with a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkoxy group having 1 to 8 carbon atoms, halogen, or a hydroxyl group),
- Y is a linear or branched alkyl group having 1 to 8 carbon atoms, a trifluoromethyl group, a linear or branched alkenyl group having 2 to 8 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, carbon Represents an alkoxy group having 1 to 8 atoms or halogen (excluding chlorine substituted at the para-position);
- n and n each independently represent 0, 1, 2 or 3;
- B represents hydrogen, a linear or branched alkyl group having 1 to 8 carbon atoms, a hydroxyl group or a trialkylsiloxy group (an alkyl group is a linear or branched alkyl group having 1 to 8 carbon atoms), R 2 R 3 and R 4 are hydrogen, a linear or branched alkyl group having 1 to 8 carbon atoms, or a pharmacologically acceptable cation, which may be the same or different. ] And a methane bisphosphonic acid derivative or a hydrate thereof as an active ingredient.
- the agent for periodontal disease referred to in the present invention is a drug effective for treating or preventing periodontal disease.
- the substituents of the methanebisphosphonic acid derivative represented by the above general formula (I) are more specifically as follows.
- Alkyl groups having 1 to 8 carbon atoms, which are straight or branched and which are unsubstituted or have a substituent of nitrogen, oxygen, or silicon atom, used as X in substituent XS are, for example, methyl, ethyl, propyl, and isopropyl.
- X is phenyl, substituted phenyl, naphthyl, substituted naphthyl.
- a linear or branched alkyl group having 1 to 8 carbon atoms may be, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, Cyclopentylmethyl, cyclohexylmethyl and the like, and a straight-chain or branched-chain alkoxy group having 1 to 8 carbon atoms, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, pentyloxy, Xyloxy and the like.
- Halogen is fluorine, chlorine, bromine, or iodine.
- the position of the substituent XS is para, meta or ortho.
- Examples of the straight-chain or branched-chain alkyl group having 1 to 8 carbon atoms of the substituent Y include methyl, ethyl, propyl, isopropyl, butyl, isoptyl, t_butyl, pentyl, hexyl, cyclopentylmethyl, cyclohexylmethyl and the like.
- Examples of the linear or branched alkenyl group having 2 to 8 carbon atoms include vinyl, aryl, 1-probenyl, isoprobenyl, pthenyl, pentenyl and the like.
- Examples of the cycloalkyl group having 3 to 8 carbon atoms include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- Examples of the alkoxy group having 1 to 8 carbon atoms include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, pentyloxy, hexyloxy and the like.
- Halogen includes fluorine, chlorine (excluding chlorine substituted at the para-position), bromine or iodine.
- the position of substitution Y is not particularly limited.
- A is-(D-iCH e and... Represents a single bond
- D is sulfur, oxygen, NR 5 (R 5 is hydrogen or a linear or branched alkyl group having 1 to 8 carbon atoms. )
- R 5 is hydrogen or a linear or branched alkyl group having 1 to 8 carbon atoms.
- CH 2 c is 0, 1, 2, or 3
- b in B is a hydroxyl group or a trialkylsiloxy group (the alkyl group is a straight or branched chain alkyl of 1-8 carbon atoms), and D is sulfur, oxygen or NR S (the same as defined above)
- B a straight-chain or branched-chain aralkyl kill group R ⁇ RR 3, R 4 and R 5 carbon atoms 1 represents 8, for example methyl, Echiru, propyl, isopropyl, heptyl, Isopuchi Le, t-heptyl, pentyl Hexyl, cyclopentylmethyl, cyclohexylmethyl and the like.
- B is a trialkylsiloxy group (the alkyl group is a linear or branched alkyl having 1 to 8 carbon atoms), the same applies to a linear or branched alkyl having 1 to 8 carbon atoms. is there.
- the pharmacologically acceptable cations represented by RR 2 , R 3 and R 4 include metal cations ON, ammonium NR 4 (where R is hydrogen or a straight-chain or branched-chain alkyl group having 1 to 8 carbon atoms) and the like.
- Particularly preferred metal cations are cations of alkali metals, such as lithium, sodium, potassium, and the like, and alkaline earth metals, such as magnesium, calcium, and the like.
- other metals, such as cations such as aluminum, zinc, and iron, are also included in the present invention.
- the ammonia includes ammonia, primary amine, secondary amine, and ammonium ammonia and quaternary ammonium.
- ammonia methylamine, dimethylamine, trimethylamine, ethylamine, getylamine, triethylamine, propylamine, jilpyramine, isopropylamine, disopylpyramine, ptyramine, dibutylamine, isobutyramine, ebuethylamine.
- ammonium such as amine, diethanolamine and triethanolamine, and tetramethylammonium and tetraethylammonium.
- cations of sodium, potassium, ammonia and alkylamine are preferred.
- the cations may be the same or different, and mixtures of cations and hydrogen, for example, monocationic salts, dicationic salts, and tricationic salts are also included in the present invention.
- the methanebisphosphonic acid derivative represented by the general formula (I) is: ⁇ All of 4 consist of hydrogen! ⁇ 1 to ⁇ are hydrogen and one is sodium or three are hydrogen and one is ammonia or two of are hydrogen and two are sodium One or two are hydrogen and the other two are ammonium.
- X is a linear or branched alkyl having 1 to 8 carbon atoms
- ⁇ is a linear or branched alkyl having 1 to 8 carbon atoms.
- a compound is preferably a branched alkyl group or a pharmacologically acceptable cation, which may be the same or different. More preferably, it is (4-methylthiophenyl) thiomethane-1,1-bisphosphonic acid.
- the methanebisphosphonic acid derivative represented by the general formula (I) can be produced by the method disclosed in Japanese Patent Publication No. Hei 8-26048.
- the methanebisphosphonic acid derivative represented by the general formula (I) or a hydrate thereof has an effect of inhibiting infiltration of inflammatory cells into periodontal tissue and destruction of alveolar bone, and is used as a periodontal agent.
- Periodontal disease is a disease of the periodontal tissue that surrounds and supports the teeth, such as the gingiva, cement trade, periodontal ligament, alveolar process bone, and supporting bone.
- gingivitis, periodontitis, apicality Periodontitis and the like Gingivitis refers to a condition in which inflammation is localized in the gingiva, the bone and periodontal ligament are not affected, and there is no tooth and gingival attachment loss.
- Periodontitis refers to a condition in which gingival inflammation extends to the periodontal ligament and alveolar bone, the pockets become periodontal pockets, and the attachment level (position of attachment) is apical from the cement enamel boundary.
- Apical periodontitis is caused by infection from the pulp through the apical foramen, trauma, hematogenous infection, mechanical or chemical irritation, etc., causing inflammation of the apical part of the tooth. It is characterized by coming.
- the compound of the present invention When used as an agent for periodontal disease, it is used as it is or as a pharmaceutical composition mixed with known pharmaceutically acceptable carriers and excipients. It is administered orally in the form of tablets, capsules, powders, granules, pills, etc., injections, syrups, ointments, buccal tablets, suppositories, mouthwashes, various forms of topical coatings, etc. Oral administration may be used. The dosage varies depending on the administration subject, administration route, symptoms, etc., but is about 0.1 mg to 5 g, preferably about lmg to 2 g, and is divided into 1 to several times a day or once a day. Administer orally or parenterally at a rate of 1 to 7 days.
- Example 1 Inhibition of Inflammatory Cell Infiltration into Periodontal Tissue of Rat Periodontal Disease Model (4-Methylthiophenyl) thiomethane-1, 1-bisphosphonic acid disodium salt (hereinafter referred to as “compound 1”)
- the following pharmacological tests were performed using The following treatments were performed in order to induce inflammatory changes in the periodontium of Rajito.
- Wistar Issa male rat 4-week-old mandibular right-turned mandible Insert a nylon thread (No. 3-0) into the interdental area between the first and second molars, and bring it down. Insertion).
- small knots were made at both ends of the nylon yarn in order to prevent the nylon yarn from falling off during the test period.
- non-insertion of nylon thread Compound 1 was dissolved in sterile distilled water as a solvent and administered subcutaneously at a rate of 2.5 mg / kg body weight to the treatment compound 1 administration group 7 days after insertion of the nylon thread and 3 weeks 5 days a week for 3 weeks . No administration was performed in the non-treated group and the untreated group in which no nylon thread was inserted. Maxillary bones were collected at 4 weeks and 8 weeks after the nylon thread was introduced.
- the collected maxilla was fixed with 10% neutral formalin solution, and then decalcified at low temperature using Planklik's demineralizing solution. Next, the maxilla was embedded in paraffin, and a mesio-distal tissue section was prepared so that the mesial roots of the first and second molars were parallel. The tissue sections were stained with hematoxylin-eosin (HE) and then histopathologically examined by light microscopy for infiltration of inflammatory cells into the periodontal tissue between the first and second molars.
- HE hematoxylin-eosin
- Example 2 Inhibition of alveolar bone resorption in rat periodontal disease model
- Example 1 In order to search the degree of alveolar bone resorption histomorphometrically, the tissue section used in Example 1 was projected onto a tablet of an image analyzer, and the first molar of the upper jaw was centrifuged and the second molar was The shortest straight line that reached the alveolar bone crest was drawn from the midpoint of the line between the cement enamel boundaries of the mesial inversion, and the distance was measured. For histomorphometric search, one individual was extracted from each group, and three tissue sections were used per individual.
- Table 3 Histomorphometric findings of rat periodontal tissue Degree of resorption of alveolar bone (4 weeks after treatment) Distance between cement enamel boundary and alveolar bone crest (average value of 3 specimens of the same individual)
- Nylon thread insertion side (right side)
- Nylon thread non-insertion side (left side)
- the histologic section used in Example 1 was projected onto a tablet of an image analyzer to search histomorphometrically for the length of exposed cement that reflects the degree of gingival regression.
- the length from the cement enamel boundary of each of the centripetal fall of the first molar and the mesial fall of the second molar was measured, and the average of both was calculated.
- For histomorphometric search one individual was extracted from each group, and three tissue sections were used per individual.
- Table 5 Histomorphometric findings of rat periodontal tissue Degree of gingival withdrawal (4 weeks after treatment) Length of exposed cementum (average value of 3 specimens of the same individual)
- Nylon thread insertion side (right side)
- Untreated individuals ⁇ 20 g 20 1.00 Untreated individuals 34.8 g 20> 1.74 'treated compound 1 treated individuals ⁇ 20 ⁇ 20 1.00 Table 6 Morphological findings of rat periodontal a ⁇ Degree of iS g in one gum (8 weeks after treatment) S cementum length (average value of 3 specimens of the same individual)
- the methanebisphosphonic acid derivative represented by the general formula (I) or a hydrate thereof according to the present invention has an effect of suppressing infiltration of inflammatory cells associated with periodontal disease, an effect of suppressing gingival regression, It has the effect of inhibiting bone resorption of bone, and is effective in treating and preventing periodontal disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00946395A EP1114642B1 (en) | 1999-07-19 | 2000-07-19 | Drugs for periodontal diseases |
US09/787,182 US6670343B1 (en) | 1999-07-19 | 2000-07-19 | Drugs for periodontal disease |
DE60043648T DE60043648D1 (de) | 1999-07-19 | 2000-07-19 | Medikamente zur behandlung von periodontalen erkrankungen |
CA002344313A CA2344313C (en) | 1999-07-19 | 2000-07-19 | Agents for periodontal disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/204808 | 1999-07-19 | ||
JP20480899 | 1999-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001005403A1 true WO2001005403A1 (fr) | 2001-01-25 |
Family
ID=16496719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004832 WO2001005403A1 (fr) | 1999-07-19 | 2000-07-19 | Medicaments pour soigner les parodontopathies |
Country Status (7)
Country | Link |
---|---|
US (1) | US6670343B1 (ja) |
EP (1) | EP1114642B1 (ja) |
CN (1) | CN100349574C (ja) |
CA (1) | CA2344313C (ja) |
DE (1) | DE60043648D1 (ja) |
ES (1) | ES2337545T3 (ja) |
WO (1) | WO2001005403A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6670343B1 (en) * | 1999-07-19 | 2003-12-30 | Toray Industries, Inc. | Drugs for periodontal disease |
WO2004019957A1 (ja) * | 2002-08-29 | 2004-03-11 | Toray Industries, Inc. | ビスホスホン酸誘導体又はその塩を有効成分とする歯周ポケット投与用医薬組成物 |
JPWO2005046702A1 (ja) * | 2003-09-19 | 2007-05-24 | サンスター株式会社 | 歯槽骨の吸収及び歯根膜喪失を抑制する方法及びそれに用いる内服組成物 |
WO2010026701A1 (ja) | 2008-09-03 | 2010-03-11 | 国立大学法人東北大学 | [4-(メチルチオ)フェニルチオ]メタンビスホスホン酸又は薬学的に許容され得るその塩を有効成分とする骨形成促進剤 |
WO2011037100A1 (ja) * | 2009-09-24 | 2011-03-31 | 日本ケミファ株式会社 | 歯周病又は根尖性歯周炎の予防又は治療剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9095517B2 (en) | 2011-10-31 | 2015-08-04 | T.F.H. Publications, Inc. | Compositions for improving the oral health of animals, methods using the same, and pet treats incorporating the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005052A1 (fr) * | 1991-09-05 | 1993-03-18 | Toray Industries, Inc. | Derive d'acide methanediphosphonique, sa production et son utilisation comme remede |
WO1993024498A1 (en) * | 1992-05-29 | 1993-12-09 | Procter & Gamble Pharmaceuticals, Inc. | Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque |
WO1996023505A1 (en) * | 1995-01-30 | 1996-08-08 | Olli Pekka Teronen | Inhibition of the degradation of connective tissue matrix protein components in mammals |
EP0911321A2 (en) * | 1997-10-10 | 1999-04-28 | Pfizer Inc. | Compounds for the treatment of osteoporosis |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5346604A (en) * | 1992-10-21 | 1994-09-13 | Diametrics Medical, Inc. | Self-activating chemical sensor system |
JPH10130284A (ja) * | 1996-11-01 | 1998-05-19 | Toray Ind Inc | メタンジホスホン酸化合物の製造法 |
US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
SG109478A1 (en) * | 1997-07-22 | 2005-03-30 | Merck & Co Inc | Method for inhibiting bone resorption |
US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
JPH1180176A (ja) * | 1997-09-04 | 1999-03-26 | Toray Ind Inc | ホスホン酸またはその塩の製造方法 |
US6555529B1 (en) * | 1997-12-25 | 2003-04-29 | Toray Industries, Inc. | Remedies for intramedullary diseases |
US5998390A (en) * | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
EP1057488A4 (en) * | 1998-12-25 | 2003-10-22 | Toray Industries | INTERLEUKIN-6 PRODUCTION INHIBITORS |
EP1114642B1 (en) * | 1999-07-19 | 2010-01-06 | Toray Industries, Inc. | Drugs for periodontal diseases |
-
2000
- 2000-07-19 EP EP00946395A patent/EP1114642B1/en not_active Expired - Lifetime
- 2000-07-19 WO PCT/JP2000/004832 patent/WO2001005403A1/ja active Application Filing
- 2000-07-19 US US09/787,182 patent/US6670343B1/en not_active Expired - Fee Related
- 2000-07-19 CN CNB008020191A patent/CN100349574C/zh not_active Expired - Fee Related
- 2000-07-19 ES ES00946395T patent/ES2337545T3/es not_active Expired - Lifetime
- 2000-07-19 DE DE60043648T patent/DE60043648D1/de not_active Expired - Lifetime
- 2000-07-19 CA CA002344313A patent/CA2344313C/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005052A1 (fr) * | 1991-09-05 | 1993-03-18 | Toray Industries, Inc. | Derive d'acide methanediphosphonique, sa production et son utilisation comme remede |
WO1993024498A1 (en) * | 1992-05-29 | 1993-12-09 | Procter & Gamble Pharmaceuticals, Inc. | Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque |
WO1996023505A1 (en) * | 1995-01-30 | 1996-08-08 | Olli Pekka Teronen | Inhibition of the degradation of connective tissue matrix protein components in mammals |
EP0911321A2 (en) * | 1997-10-10 | 1999-04-28 | Pfizer Inc. | Compounds for the treatment of osteoporosis |
Non-Patent Citations (2)
Title |
---|
AOKI TAKEHITO ET AL.: "The effects of bisphosphonates on polymorphonuclear leykocyte-derived matrix metalloproteinase activity", NIPPON SHISHUBYO GAKKAI KAISHI,, vol. 41, no. 2, 1999, pages 99 - 107, XP002930734 * |
See also references of EP1114642A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6670343B1 (en) * | 1999-07-19 | 2003-12-30 | Toray Industries, Inc. | Drugs for periodontal disease |
WO2004019957A1 (ja) * | 2002-08-29 | 2004-03-11 | Toray Industries, Inc. | ビスホスホン酸誘導体又はその塩を有効成分とする歯周ポケット投与用医薬組成物 |
JPWO2005046702A1 (ja) * | 2003-09-19 | 2007-05-24 | サンスター株式会社 | 歯槽骨の吸収及び歯根膜喪失を抑制する方法及びそれに用いる内服組成物 |
US7993684B2 (en) | 2003-09-19 | 2011-08-09 | Sunstar Inc. | Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein |
WO2010026701A1 (ja) | 2008-09-03 | 2010-03-11 | 国立大学法人東北大学 | [4-(メチルチオ)フェニルチオ]メタンビスホスホン酸又は薬学的に許容され得るその塩を有効成分とする骨形成促進剤 |
WO2011037100A1 (ja) * | 2009-09-24 | 2011-03-31 | 日本ケミファ株式会社 | 歯周病又は根尖性歯周炎の予防又は治療剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1322135A (zh) | 2001-11-14 |
CA2344313C (en) | 2007-11-27 |
CN100349574C (zh) | 2007-11-21 |
CA2344313A1 (en) | 2001-01-25 |
EP1114642B1 (en) | 2010-01-06 |
EP1114642A1 (en) | 2001-07-11 |
DE60043648D1 (de) | 2010-02-25 |
EP1114642A4 (en) | 2007-12-12 |
US6670343B1 (en) | 2003-12-30 |
ES2337545T3 (es) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2825654B2 (ja) | アレンドロナートによる歯周病の治療 | |
CA2351617C (en) | Method for inhibiting dental resorptive lesions | |
CA2211783A1 (en) | Inhibition of the degradation of connective tissue matrix protein components in mammals | |
Levy et al. | Histologic study of the effects of occlusal hypofunction following antagonist tooth extraction in the rat | |
Lasfargues et al. | Effect of indomethacin on bone destruction during experimental periodontal disease in the hamster | |
WO2001005403A1 (fr) | Medicaments pour soigner les parodontopathies | |
JP4824954B2 (ja) | 口内炎治療のための口腔用組成物 | |
US20180085374A1 (en) | Use of Morpholino Compounds for the Treatment of Halitosis | |
JPS63287719A (ja) | 歯槽骨代謝治療用組成物 | |
WO2018221447A1 (ja) | 骨再生剤 | |
JP6824015B2 (ja) | 歯槽骨吸収抑制剤 | |
US6682718B1 (en) | Remedies for periodontosis | |
Nascimento et al. | Periodontal changes in distant teeth due to trauma from occlusion | |
Van Dijk et al. | Artificial Periodontal Defects in Beagle Dogs: A Clinical Evaluation During 24 Months | |
JPWO2004019957A1 (ja) | ビスホスホン酸誘導体又はその塩を有効成分とする歯周ポケット投与用医薬組成物 | |
JPS61233612A (ja) | チユ−インガム | |
EP1536803A2 (en) | Use of bisphosphonic acid derivatives for the treatment of calcium phrophosphated deposition disease and dental treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00802019.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2001 510458 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2344313 Country of ref document: CA Ref document number: 2344313 Country of ref document: CA Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000946395 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09787182 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000946395 Country of ref document: EP |